A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, ...

A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, ...

Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies ...

Folate is a B vitamin that's crucial for cell growth and a healthy pregnancy. Dietitians share 9 folate-rich foods to eat to up your intake. April 15, 2025, 1:51 PM EDT / Source : TODAY ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

About Diffuse Large B-Cell Lymphoma. Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma in the U.S ...

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

Most patients who have a relapse after anti-CD19 CAR T-cell therapy or have resistance to such therapy continue to have CD19 expression on malignant B cells. 11 Although CD19 antigen loss can ...

An "armored" CAR T cell therapy engineered to secrete interleukin-18 (IL 18) demonstrated cancer reduction in 81% and complete remission in 52% of patients with treatment-resistant B-cell lymphomas.